Searchable abstracts of presentations at key conferences on calcified tissues

ba0003pp322 | Osteoporosis: treatment | ECTS2014

Non attendance at a Bone Health Clinic following hip fracture

Maher Niamh , Steen Georgina , Fallon Nessa , Lannon Rosaleen , Casey Miriam , Walsh J B

Hip fractures are a major cause of burden in terms of mortality, disability, and costs. In Ireland, 3000 hip fracture occur annually and is expected to increase over the coming years1. Estimated cost of hip fractures is &z.euro;14 300/admission2. Outpatient non-attendance is a source of inefficiency, wasting time, resources and lengthens waiting lists. Non attendees have a significant negative impact on productivity, their own care and resources. In 2008,...

ba0005p351 | Osteoporosis: pathophysiology and epidemiology | ECTS2016

Gender differences in presentation and outcomes in older hip fracture patients

Maher Niamh , Steen Georgina , Fallon Nessa , Browne Joseph , Walsh James Bernard , Casey Miriam

Introduction: Hip fracture is a significant health problem with 25–30% occurring in men. Outcome differences between the genders have been documented, particularly mortality rates.Aim: To prospectively investigate outcomes of elderly hip fracture patients regarding mortality, recovery of function, quality of life, incidence of osteoporosis, osteoporosis knowledge, medication adherence, nutritional status and fear of falling.Me...

ba0005p406 | Osteoporosis: treatment | ECTS2016

Adherence and persistence to teriparatide treatment in patients attending a specialised Bone Health Service

Steen Georgina , Maher Niamh , Fallon Nessa , Dillon Aoife , Mahon James , Lannon Rosaleen , McCarroll Kevin , Walsh J B , Casey Miriam

Introduction: Osteoporosis affects the bones causing weak or brittle bones and increasing the risk of fracture. Efficacy of anti-osteoporotic treatment is based on drug potency and adherence and persistence. Teriparatide (TPTD) is the first anabolic agent developed for the treatment of osteoporosis. It is usually given as a daily subcutaneous injection for a two-year treatment course.Aim: To evaluate adherence and persistence to TPTD treatment in patient...